Palvella Therapeutics (PVLA) Cash & Equivalents (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Cash & Equivalents data on file, last reported at $206.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $206.4 million, up 172.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $206.4 million (up 172.91% YoY), and the FY2025 annual result was $58.0 million, down 30.65% from the prior year.
• Cash & Equivalents grew to $206.4 million in Q1 2026 per PVLA's latest filing, from $58.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $206.4 million in Q1 2026 and troughed at $6.2 million in Q1 2024.
• A 5-year average of $56.7 million and a median of $54.3 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 84.28% in 2024, then jumped 1110.4% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $38.6 million in 2022, then plunged by 80.98% to $7.4 million in 2023, then jumped by 1037.44% to $83.6 million in 2024, then sank by 30.65% to $58.0 million in 2025, then soared by 255.96% to $206.4 million in 2026.
• Business Quant data shows PVLA's Cash & Equivalents at $206.4 million in Q1 2026, $58.0 million in Q4 2025, and $63.6 million in Q3 2025.